Kiora Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$ 321,439us-gaap_ResearchAndDevelopmentExpense	$ 217,868us-gaap_ResearchAndDevelopmentExpense	$ 531,116us-gaap_ResearchAndDevelopmentExpense	$ 1,010,268us-gaap_ResearchAndDevelopmentExpense
General and administrative	782,846us-gaap_GeneralAndAdministrativeExpense	656,216us-gaap_GeneralAndAdministrativeExpense	1,930,967us-gaap_GeneralAndAdministrativeExpense	2,087,637us-gaap_GeneralAndAdministrativeExpense
Total operating expenses	1,104,285us-gaap_OperatingExpenses	874,084us-gaap_OperatingExpenses	2,462,083us-gaap_OperatingExpenses	3,097,905us-gaap_OperatingExpenses
Other income (expense), net:
Research & development tax credit	0eyeg_ResearchAndDevelopmentTaxCredit	2,940eyeg_ResearchAndDevelopmentTaxCredit	15,911eyeg_ResearchAndDevelopmentTaxCredit	24,520eyeg_ResearchAndDevelopmentTaxCredit
Interest income	164us-gaap_InvestmentIncomeInterest	307us-gaap_InvestmentIncomeInterest	1,102us-gaap_InvestmentIncomeInterest	2,186us-gaap_InvestmentIncomeInterest
Extinguishment of research liability			240,000us-gaap_ExtinguishmentOfDebtAmount	0us-gaap_ExtinguishmentOfDebtAmount
Interest expense	(1,920,146)us-gaap_InterestExpense	(32,055)us-gaap_InterestExpense	(441,720)us-gaap_InterestExpense	(611,386)us-gaap_InterestExpense
Change in warrant liability	223,172us-gaap_FairValueAdjustmentOfWarrants	0us-gaap_FairValueAdjustmentOfWarrants	1,095,282us-gaap_FairValueAdjustmentOfWarrants	0us-gaap_FairValueAdjustmentOfWarrants
Other income (expense), net	10us-gaap_OtherNonoperatingIncomeExpense	0us-gaap_OtherNonoperatingIncomeExpense
Total other expense, net	(1,696,801)us-gaap_NonoperatingIncomeExpense	(28,808)us-gaap_NonoperatingIncomeExpense	910,575us-gaap_NonoperatingIncomeExpense	(584,680)us-gaap_NonoperatingIncomeExpense
Net Loss	(2,801,086)	(902,892)	(1,551,508)	(3,682,585)
Deemed dividend on preferred stock	(8,222,008)	0
Net income attributable to non-controlling interests	(5,177)	(58,948)	(222,484)	(196,862)
Net (loss) attributable to Eyegate Pharmaceuticals, Inc. stockholders	(11,028,271)	(961,840)	(1,773,992)	(3,879,447)
Net loss per common share - basic and diluted	$ (3.23)us-gaap_EarningsPerShareBasicAndDiluted	$ (0.47)us-gaap_EarningsPerShareBasicAndDiluted	$ (9.20)us-gaap_EarningsPerShareBasicAndDiluted	$ (21.03)us-gaap_EarningsPerShareBasicAndDiluted
Weighted average shares outstanding - basic and diluted	3,417,509	2,025,527	192,873	184,431
Net loss	(2,801,086)us-gaap_ProfitLoss	(902,892)us-gaap_ProfitLoss	(1,551,508)us-gaap_ProfitLoss	(3,682,585)us-gaap_ProfitLoss
Other comprehensive income (loss):
Foreign currency translation adjustments	51,325	8,994	5,510	22,637
Comprehensive income (loss)	(2,749,761)	(911,886)	5,510	22,637
Less:
Net income attributable to non-controlling interests	(5,177)	(58,948)	(222,484)	(196,862)
Other comprehensive (income) loss attributable to non-controlling interests	32,967	(6,819)	(1,889)	(8,827)
Comprehensive income attributable to non-controlling interests	27,790	(65,767)	(224,373)	(205,689)
Comprehensive loss attributable to Eyegate Pharmaceuticals, Inc. stockholders	$ (2,721,971)us-gaap_ComprehensiveIncomeNetOfTax	$ (959,665)us-gaap_ComprehensiveIncomeNetOfTax	$ (1,770,371)us-gaap_ComprehensiveIncomeNetOfTax	$ (3,865,637)us-gaap_ComprehensiveIncomeNetOfTax